Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Neutral

LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS

LSL Pharma Delivers Revenue Surge But Profitability Erosion Signals Costly Growth Phase

By The Northwire Desk — AI Analysis Apr 30, 2026 · 07:00 LSL · 0.42 LSL Pharma Group Inc.
Executive Summary
  • LSL Pharma Group reported FY-25 record revenues of $28.7M, a 62% increase year-over-year driven by CMO segment growth (+142%).
  • Net income swung to a loss of $2.8M in FY-25 compared to net income of $3.3M in FY-24, primarily due to non-recurrent charges and regulatory-related production halts.
  • EBITDA declined significantly from $6.8M in FY-24 to $2.7M in FY-25, indicating margin compression despite top-line expansion.
  • The company completed acquisitions of Laboratoire Du-Var Inc. (Nov 2025) and Juno OTC Inc. (Jan 2026), adding product portfolios and manufacturing capacity.
  • Financing secured includes $12M convertible debentures (closed Dec 2025) and a credit facility increase to $11M in April 2026, totaling $23.2M long-term debt/capital raised.
  • US-FDA certification for the Steri-Med plant was obtained in Jan 2026, enabling ophthalmic ointment manufacturing for the U.S. market.
  • A 3-month production halt occurred at Steri-Med (Jan-Mar 2026) to implement corrective actions following a Health Canada inspection; full production resumed April 2, 2026.
Material Impact
  • The revenue growth of 62% is positive but does not offset the deterioration in profitability, as evidenced by the swing from net income to a $2.8M loss.
  • EBITDA contraction of over 60% suggests that integration costs and regulatory compliance expenses are currently outweighing operational efficiencies.
  • The production halt represents an execution risk that directly impacted Q4 results; while resolved, it highlights vulnerability in manufacturing continuity.
  • Financing terms include a $12M convertible debenture at $0.45 conversion price with 10% interest, creating significant dilution pressure if the stock remains below this level until maturity (Dec 2029).
  • The news confirms previously announced M&A and financing activities; therefore, it is largely priced in rather than a new catalyst.
  • No material negative surprises regarding debt covenants or liquidity were disclosed, as capital was successfully raised to fund operations.
LSL · Price
Company Overview
  • LSL Pharma Group operates in pharmaceuticals with a focus on Contract Manufacturing Organization (CMO) services and Over-The-Counter (OTC) consumer health products.
  • Flagship manufacturing facility is Steri-Med Pharma Inc., which recently secured US-FDA certification for ophthalmic ointments, opening access to the U.S. market.
  • The company has expanded its portfolio through acquisitions of Laboratoire Du-Var (cosmetics/personal care) and Juno OTC (OTC drugs/medical devices).
  • Strategic focus is on vertical integration, combining manufacturing capacity with commercial distribution networks in Canada and the U.S.
Read the original news release →

More from LSL Pharma Group Inc.

May 28, 2026 · 07:00

Revenue Growth Masks Profitability Concerns as Operational Scaling Continues

Production / Operations May 25, 2026 · 12:00

Revenue Surge Masks Cash Burn Risk as Integration Costs Mount

Earnings May 25, 2026 · 07:00

Revenue Surge Masks Integration Costs as LSL Pharma Tests Regulatory Resilience

Earnings Apr 09, 2026 · 07:00

Juno OTC secures Loratadine RDT partnership, expanding Canadian OTC pipeline

M&A / Property Jan 28, 2026 · 16:07

LSL obtains FDA certification for ophthalmic ointments

Production / Operations Jan 28, 2026 · 07:00

LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES

Production / Operations